Sight Sciences (NASDAQ: SGHT) recently received a number of ratings updates from brokerages and research firms:
- 11/14/2026 – Sight Sciences was downgraded by Wall Street Zen from “buy” to “hold”.
- 11/12/2026 – Sight Sciences had its price target raised by UBS Group from $8.00 to $13.50. They now have a “buy” rating on the stock.
- 11/5/2026 – Sight Sciences had its “overweight” rating reaffirmed by Piper Sandler. They now have a $12.00 price target on the stock, up from $9.00.
- 11/4/2026 – Sight Sciences had its “sell (e+)” rating reaffirmed by Weiss Ratings.
- 10/15/2026 – Sight Sciences is now covered by HC Wainwright. They set a “buy” rating and a $14.00 price target on the stock.
- 10/5/2026 – Sight Sciences had its price target raised by Citigroup from $8.00 to $10.00. They now have a “neutral” rating on the stock.
Sight Sciences Stock Performance
SGHT stock traded down $0.10 during trading on Tuesday, hitting $10.49. The company had a trading volume of 271,335 shares, compared to its average volume of 405,123. The firm has a market cap of $583.03 million, a PE ratio of -20.17 and a beta of 2.44. Sight Sciences, Inc. has a 1-year low of $3.38 and a 1-year high of $11.60. The firm has a 50-day moving average price of $9.01 and a 200-day moving average price of $6.23. The company has a quick ratio of 4.72, a current ratio of 5.04 and a debt-to-equity ratio of 0.71.
Sight Sciences (NASDAQ:SGHT – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). Sight Sciences had a negative return on equity of 43.91% and a negative net margin of 32.13%. The firm had revenue of $24.92 million during the quarter, compared to the consensus estimate of $23.55 million. On average, analysts expect that Sight Sciences, Inc. will post -0.48 earnings per share for the current year.
Insider Buying and Selling
In related news, CTO David Badawi sold 7,797 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $9.05, for a total transaction of $70,562.85. Following the completion of the sale, the chief technology officer directly owned 1,975,075 shares of the company’s stock, valued at $17,874,428.75. This trade represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Brenton Taylor sold 2,988 shares of Sight Sciences stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $8.85, for a total transaction of $26,443.80. Following the completion of the transaction, the executive vice president owned 261,990 shares in the company, valued at approximately $2,318,611.50. This trade represents a 1.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 47,646 shares of company stock worth $429,157. 30.40% of the stock is currently owned by company insiders.
Sight Sciences is a medical technology company that develops and commercializes devices for ophthalmic care, with a focus on glaucoma and dry eye disease. Its products are designed to support minimally invasive procedures and address underlying causes of these conditions. The company’s portfolio includes the OMNI Surgical System, used in procedures to reduce eye pressure in patients with glaucoma, and TearCare, a device-based treatment for evaporative dry eye associated with meibomian gland dysfunction.
Read More
- Five stocks we like better than Sight Sciences
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Sight Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.
